Silvia Alberti Violetti

Real-world effectiveness of topical ruxolitinib in non-segmental vitiligo: repigmentation, mental health, and quality-of-life outcomes in an 860-patient multicentre study

Angelo V Marzano, Alessandra Narcisi, Gianluca Tavoletti, Luisa C Rossi et autres

BACKGROUND: Vitiligo affects 0·5-2% of the global population and carries a substantial psychosocial burden. Topical ruxolitinib 1·5% cream is approved for non-segmental vitiligo based on phase-3 trial data, but real-world evidence across heterogeneous populations remains limited. OBJECTIVES: To evaluate the real-world effectiveness, …

it, us (code pays fourni par la source)

Klinische Ergebnisse von Chlormethin‐Gel bei Mycosis fungoides in “sensiblen” Bereichen: Eine retrospektive Fallserie

Gianluca Tavoletti, Gianluca Avallone, Pamela Vezzoli, Paolo Sena et autres

chlormethine, cutaneous lymphomas, Mycosis fungoides Sehr geehrte Herausgeber, Chlormethin (CL)-Gel ist das erste topische Therapeutikum, das zur Behandlung der Mycosis fungoides (MF) entwickelt wurde. 1 In internationalen Leitlinien wird es zur Erstlinientherapie für erwachsene Patienten mit MF im Frühstadium (IA-IIA) und in …

it (code pays fourni par la source)

Real-world effectiveness and safety of mogamulizumab in mycosis fungoides and Sézary syndrome: A multicenter observational study by the Italian Lymphoma Foundation (FIL)

Gabriele Roccuzzo, Paolo Fava, Serena Rupoli, Erika Morsia et autres

Marginal zone lymphoma with cutaneous presentation and circulating clonal B-cells

Giorgio Alberto Croci, Silvia Alberti Violetti, Maxime Battistella, Adèle de Masson

Symptom burden and health-related quality of life in patients with Mycosis Fungoides and Sezary Syndrome: findings from the International PROSPER study

Julia Scarisbrick, Larisa J. Geskin, Sima Rozati, Erika Morsia et autres

Clinical outcomes of chlormethine gel in mycosis fungoides affecting “sensitive” areas: A retrospective case series

Gianluca Tavoletti, Gianluca Avallone, Pamela Vezzoli, Paolo Sena et autres

Dear Editors,Chlormethine (CL) gel is the first skin-directed therapy developed for the treatment of mycosis fungoides (MF). 1 It is recommended as a first-line treatment for adult patients with early-stage MF (IA-IIA) and, in combination with systemic therapies, for those in advanced …

it (code pays fourni par la source)

Effectiveness of Total-Body Screening Examination in Diagnosing Melanoma at Earlier Stages: A Cohort Study

Camila Caraviello, Gianluca Nazzaro, Silvia Alberti Violetti, Emanuela Passoni et autres

Background/ Objectives: Melanoma is the most severe form of skin cancer, with incidence increasing worldwide. However, there is still a lack of strong evidence to support melanoma screening, and screening strategies vary among healthcare systems. This study aims to compare the effectiveness …

it (code pays fourni par la source)

Italian expert opinion on the treatment of mycosis fungoides with chlormethine gel: Results of a Delphi consensus

Silvia Alberti Violetti, Marco Ardigò, Raffaele Filotico, Pietro Quaglino et autres

Background Mycosis fungoides (MF) is the most common form of a rare cutaneous T-cell lymphoma, often present with patches or plaques on the skin and characterized of malignant T cell infiltration. Topical Chlormethine (CL) gel has been approved by EMA for treatment …

it, by (code pays fourni par la source)

Multidisciplinary and personalized approach to the management of mycosis fungoides with chlormethine gel: a collection of clinical experiences

Silvia Alberti Violetti, Marco Ardigò, Paolo Fava, Giuseppe Gritti et autres

Topical chlormethine (CL) gel formulation was approved by the EMA in 2017 for the treatment of adult patients with mycosis fungoides (MF). To expand the knowledge on the management of MF, this paper provides an overview of clinical practice evidence about the …

it (code pays fourni par la source)

A-219 Italian expert opinion on the treatment of mycosis fungoides with chlormethine gel: results of a Delphi consensus

Silvia Alberti Violetti, Marco Ardigò, Raffaele Filotico, Pietro Quaglino et autres

A-231 Mogamulizumab in Patients with Sézary Syndrome and Mycosis Fungoides Over 75 Years of Age: Real-World Data from 7 Italian Centers

Erika Morsia, Corrado Zengarini, G. Rocuzzo, Paolo Fava et autres

A-230 Overlap: mycosis fungoides/Sezary syndrome and inflammatory dermatosis, a case series

Giorgio Alberto Croci, Silvia Tabano, Italo Francesco Aromolo, Silvia Alberti Violetti et autres